\-\ Texto\\:\\ \ \(0\)\
\-\ scars\\ on\\ abdomen\\ from\\ previous\\ surgeries\\.\\ physical\\ exam\\ is\\ otherwise\\ unremarkable\\.\ \(0\)\
\-\ patient\\ treated\\ with\\ xelox\\ \\[capecitabine\\ plus\\ oxiliplatin\\]chemotherapy\\.\\ repeat\\ imaging\\ has\\ showed\\ modest\\ decrease\\ in\\ the\\ size\\ of\\ his\\ hepatic\\ lesion\\.\\ typically\\ patients\\ with\\ metastases\\ this\\ advanced\\ have\\ very\\ poor\\ prognosis\\.\ \(0\)\
\-\ the\\ first\\ image\\ shows\\ a\\ 1\\ x\\ 1\\ cm\\ area\\ of\\ hypoattnuation\\ in\\ the\\ left\\ lobe\\ of\\ the\\ liver\\.\\ this\\ was\\ the\\ image\\ taken\\ when\\ the\\ patient\\ presented\\ with\\ his\\ abdominal\\ complaints\\.\\ his\\ symptoms\\ resolved\\ and\\ he\\ failed\\ to\\ follow\\ up\\.\\ the\\ second\\ and\\ third\\ images\\ are\\ from\\ a\\ year\\ later\\.\\ they\\ show\\ a\\ left\\ hepatic\\ lobe\\ mass\\ that\\ has\\ diminished\\ attenuation\\ and\\ heterogeneous\\ enhancement\\.\\ \\ the\\ mass\\ measures\\ approximately\\ 4\\ x\\ 4cm\\ and\\ there\\ is\\ intrahepatic\\ ductal\\ dilatation\\ distal\\ to\\ the\\ mass\\ lesion\ \(0\)\
\-\ metastatic\\ colon\\ cancer\ \(1\)\
\-\ 1\\.\\ metastatic\\ colon\\ cancer\ \(0\)\
\-\ 2\\.\\ primary\\ cholangiocarcinoma\\,\\ or\\ hepatocellular\\ carcinoma\ \(0\)\
\-\ 3\\.\\ benign\\ hepatoma\ \(0\)\
\-\ 69\\ year\\ old\\ male\\ with\\ remote\\ history\\ of\\ colon\\ cancer\\ status\\ post\\ total\\ colectomy\\ 9\\ years\\ ago\\ presents\\ with\\ unintentional\\ weight\\ loss\\ and\\ vague\\ abdominal\\ pain\\.\\ patient\\ currently\\ smokes\\ 1\\/2\\ pack\\/day\\.\ \(0\)\
\-\ past\\ medical\\ history\\ notable\\ for\\:\ \(0\)\
\-\ diabetes\\ mellitus\\ type\\ 2\\,\ \(1\)\
\-\ hypertension\\,\ \(74\)\
\-\ atrial\\ fibrillation\ \(35\)\
\-\ this\\ case\\ brings\\ to\\ light\\ the\\ utility\\ of\\ ct\\ in\\ the\\ post\\ operative\\ period\\ as\\ a\\ method\\ of\\ surveillance\\ for\\ recurrence\\ and\\ or\\ metastases\\ of\\ a\\ primary\\ colon\\ cancer\\.\\ in\\ 2005\\,\\ the\\ american\\ society\\ of\\ clinical\\ oncology\\ \\[asca\\]\\ updated\\ their\\ post\\ resection\\ surveillance\\ recommendations\\ to\\ include\\ yearly\\ ct\\ for\\ patients\\ who\\ had\\ stage\\ ii\\ or\\ worse\\ disease\\.\\ they\\ had\\ previously\\ recommended\\ against\\ ct\\ monitoring\\ but\\ unanimously\\ changed\\ their\\ recommendation\\ after\\ 3\\ meta\\-analyses\\ all\\ showed\\ significant\\ decrease\\ in\\ mortality\\ when\\ post\\ op\\ ct\\ surveillance\\ was\\ done\\.\\ the\\ decrease\\ was\\ due\\ to\\ early\\ identification\\ of\\ resectable\\ hepatic\\ metastases\\!\ \(0\)\
\-\ asca\\ recommended\\ a\\ surveillance\\ period\\ of\\ 3\\ years\\ based\\ on\\ the\\ average\\ length\\ of\\ the\\ meta\\-analyses\\.\\ given\\ that\\ our\\ patient\\ was\\ 9\\ years\\ post\\ resection\\,\\ these\\ guidelines\\ would\\ not\\ have\\ affected\\ his\\ outcome\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ surveillance\\:\\ 0\\.26749355366735933\ \(0\)\
\-\ asca\\:\\ 0\\.19577641950434257\ \(0\)\
\-\ colon\\:\\ 0\\.18642536933505685\ \(0\)\
\-\ the\\:\\ 0\\.1832043703436189\ \(0\)\
\-\ post\\:\\ 0\\.16653173315519085\ \(0\)\
\-\ cancer\\:\\ 0\\.16308090903199446\ \(0\)\
\-\ decrease\\:\\ 0\\.1578337169440298\ \(0\)\
\-\ his\\:\\ 0\\.1484897007938273\ \(0\)\
\-\ metastases\\:\\ 0\\.14845476002650781\ \(0\)\
\-\ hepatic\\:\\ 0\\.14623379840446013\ \(0\)\
\-\ of\\:\\ 0\\.13176391371717183\ \(0\)\
\-\ years\\:\\ 0\\.11256284126262324\ \(0\)\
\-\ period\\:\\ 0\\.10703250509344805\ \(0\)\
\-\ their\\:\\ 0\\.10160098191462855\ \(0\)\
\-\ xelox\\:\\ 0\\.09788820975217129\ \(0\)\
\-\ capecitabine\\:\\ 0\\.09788820975217129\ \(0\)\
\-\ oxiliplatin\\:\\ 0\\.09788820975217129\ \(0\)\
\-\ hypoattnuation\\:\\ 0\\.09788820975217129\ \(0\)\
\-\ unanimously\\:\\ 0\\.09788820975217129\ \(0\)\
\-\ recommended\\:\\ 0\\.09737942486806885\ \(0\)\
\-\ ct\\:\\ 0\\.09321297654733225\ \(0\)\
\-\ they\\:\\ 0\\.0874714478125258\ \(0\)\
\-\ modest\\:\\ 0\\.08609966948680343\ \(0\)\
\-\ was\\:\\ 0\\.0853292462278932\ \(0\)\
\-\ hepatoma\\:\\ 0\\.0830127281429798\ \(0\)\
\-\ smokes\\:\\ 0\\.0830127281429798\ \(0\)\
\-\ brings\\:\\ 0\\.08174887002603132\ \(0\)\
\-\ showed\\:\\ 0\\.08154045451599723\ \(0\)\
\-\ patient\\:\\ 0\\.07963423746606617\ \(0\)\
\-\ resectable\\:\\ 0\\.07959559484611971\ \(0\)\
\-\ unintentional\\:\\ 0\\.07866192868220769\ \(0\)\
\-\ resection\\:\\ 0\\.07847288812706432\ \(0\)\
\-\ image\\:\\ 0\\.07829216467129596\ \(0\)\
\-\ utility\\:\\ 0\\.07700783149540073\ \(0\)\
\-\ updated\\:\\ 0\\.07700783149540073\ \(0\)\
\-\ to\\:\\ 0\\.07651197253028684\ \(0\)\
\-\ in\\:\\ 0\\.0761353807599545\ \(0\)\
\-\ and\\:\\ 0\\.07588985575751496\ \(0\)\
\-\ society\\:\\ 0\\.07557498733838405\ \(0\)\
\-\ primary\\:\\ 0\\.07527516585820057\ \(0\)\
\-\ plus\\:\\ 0\\.07492446139513052\ \(0\)\
\-\ recommendation\\:\\ 0\\.07431112922143557\ \(0\)\
\-\ guidelines\\:\\ 0\\.07431112922143557\ \(0\)\
\-\ when\\:\\ 0\\.07394883489621802\ \(0\)\
\-\ colectomy\\:\\ 0\\.07373096675506273\ \(0\)\
\-\ yearly\\:\\ 0\\.07215785404152396\ \(0\)\
\-\ scars\\:\\ 0\\.07168086921408484\ \(0\)\
\-\ recommendations\\:\\ 0\\.07122418787761194\ \(0\)\
\-\ lobe\\:\\ 0\\.07074589224680498\ \(0\)\
\-\ mass\\:\\ 0\\.07014182552346689\ \(0\)\
\-\ patients\\:\\ 0\\.06886801148743489\ \(0\)\
\-\ fibrillation\\:\\ 0\\.06847792250502488\ \(0\)\
\-\ changed\\:\\ 0\\.06847792250502488\ \(0\)\
\-\ cholangiocarcinoma\\:\\ 0\\.0681372465337883\ \(0\)\
\-\ mellitus\\:\\ 0\\.0681372465337883\ \(0\)\
\-\ identification\\:\\ 0\\.06780705458075184\ \(0\)\
\-\ method\\:\\ 0\\.06748672059053477\ \(0\)\
\-\ metastatic\\:\\ 0\\.06714131071536437\ \(0\)\
\-\ abdominal\\:\\ 0\\.06695480987082654\ \(0\)\
\-\ oncology\\:\\ 0\\.06547786739927537\ \(0\)\
\-\ outcome\\:\\ 0\\.06521929123003287\ \(0\)\
\-\ surgeries\\:\\ 0\\.0649667997741795\ \(0\)\
\-\ 4cm\\:\\ 0\\.06447897068935031\ \(0\)\
\-\ intrahepatic\\:\\ 0\\.06424312840948909\ \(0\)\
\-\ 69\\:\\ 0\\.06424312840948909\ \(0\)\
\-\ or\\:\\ 0\\.06388166875190247\ \(0\)\
\-\ average\\:\\ 0\\.06378644707301619\ \(0\)\
\-\ remote\\:\\ 0\\.06334841107880929\ \(0\)\
\-\ this\\:\\ 0\\.06309863568881742\ \(0\)\
\-\ hepatocellular\\:\\ 0\\.06292755746101075\ \(0\)\
\-\ against\\:\\ 0\\.06194242648969487\ \(0\)\
\-\ failed\\:\\ 0\\.061755806276760285\ \(0\)\
\-\ notable\\:\\ 0\\.06121466345983602\ \(0\)\
\-\ have\\:\\ 0\\.06115556384102241\ \(0\)\
\-\ monitoring\\:\\ 0\\.06104018170042913\ \(0\)\
\-\ had\\:\\ 0\\.060994203806048156\ \(0\)\
\-\ diminished\\:\\ 0\\.06069950572919255\ \(0\)\
\-\ mortality\\:\\ 0\\.060207951460582075\ \(0\)\
\-\ with\\:\\ 0\\.0599284739201001\ \(0\)\
\-\ vague\\:\\ 0\\.059892328948716975\ \(0\)\
\-\ lesion\\:\\ 0\\.05869092784772873\ \(0\)\
\-\ 2005\\:\\ 0\\.0581717894952956\ \(0\)\
\-\ advanced\\:\\ 0\\.05752905896958376\ \(0\)\
\-\ atrial\\:\\ 0\\.05752905896958376\ \(0\)\
\-\ op\\:\\ 0\\.05752905896958376\ \(0\)\
\-\ has\\:\\ 0\\.05591794284652032\ \(0\)\
\-\ diabetes\\:\\ 0\\.055910670274213536\ \(0\)\
\-\ length\\:\\ 0\\.05580389932587606\ \(0\)\
\-\ for\\:\\ 0\\.055656897313198214\ \(0\)\
\-\ resolved\\:\\ 0\\.05498594983134837\ \(0\)\
\-\ our\\:\\ 0\\.054225958539466525\ \(0\)\
\-\ prognosis\\:\\ 0\\.05386523913547236\ \(0\)\
\-\ ductal\\:\\ 0\\.05386523913547236\ \(0\)\
\-\ repeat\\:\\ 0\\.053689327133907505\ \(0\)\
\-\ that\\:\\ 0\\.05312574023579973\ \(0\)\
\-\ light\\:\\ 0\\.05301317330224964\ \(0\)\
\-\ american\\:\\ 0\\.05222381813652378\ \(0\)\
\-\ poor\\:\\ 0\\.05163164627687251\ \(0\)\
\-\ operative\\:\\ 0\\.05134738086439479\ \(0\)\
\-\ worse\\:\\ 0\\.05127747578475339\ \(0\)\
\-\ recurrence\\:\\ 0\\.05053715524407084\ \(0\)\
\-\ complaints\\:\\ 0\\.050407871851564\ \(0\)\
\-\ affected\\:\\ 0\\.05034380962084137\ \(0\)\
\-\ total\\:\\ 0\\.050153886224327\ \(0\)\
\-\ dilatation\\:\\ 0\\.04996726601139242\ \(0\)\
\-\ measures\\:\\ 0\\.049905773626634474\ \(0\)\
\-\ previously\\:\\ 0\\.049136876792700145\ \(0\)\
\-\ taken\\:\\ 0\\.04891096546382468\ \(0\)\
\-\ stage\\:\\ 0\\.04874459946815338\ \(0\)\
\-\ done\\:\\ 0\\.04868971243403442\ \(0\)\
\-\ from\\:\\ 0\\.048620080767147585\ \(0\)\
\-\ ii\\:\\ 0\\.04826043952057116\ \(0\)\
\-\ currently\\:\\ 0\\.04701998466649684\ \(0\)\
\-\ attenuation\\:\\ 0\\.046834172373735376\ \(0\)\
\-\ hypertension\\:\\ 0\\.046834172373735376\ \(0\)\
\-\ history\\:\\ 0\\.04677157203806428\ \(0\)\
\-\ third\\:\\ 0\\.04660634233376421\ \(0\)\
\-\ previous\\:\\ 0\\.046251586329311756\ \(0\)\
\-\ second\\:\\ 0\\.045824024120001056\ \(0\)\
\-\ ago\\:\\ 0\\.04478607733192803\ \(0\)\
\-\ based\\:\\ 0\\.044338912973262305\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.04430247697297591\ \(0\)\
\-\ early\\:\\ 0\\.04412213000884567\ \(0\)\
\-\ very\\:\\ 0\\.04390964005979904\ \(0\)\
\-\ later\\:\\ 0\\.04380495248041757\ \(0\)\
\-\ otherwise\\:\\ 0\\.043632711354089235\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.0434631913707087\ \(0\)\
\-\ would\\:\\ 0\\.04332947759342621\ \(0\)\
\-\ typically\\:\\ 0\\.04297013104696825\ \(0\)\
\-\ status\\:\\ 0\\.042716145419731254\ \(0\)\
\-\ weight\\:\\ 0\\.04268481578645536\ \(0\)\
\-\ liver\\:\\ 0\\.04222552777153548\ \(0\)\
\-\ given\\:\\ 0\\.042106299969632936\ \(0\)\
\-\ benign\\:\\ 0\\.04204717920424019\ \(0\)\
\-\ left\\:\\ 0\\.041760172208529595\ \(0\)\
\-\ size\\:\\ 0\\.04144531725266813\ \(0\)\
\-\ first\\:\\ 0\\.041306858663557634\ \(0\)\
\-\ type\\:\\ 0\\.04106204823292431\ \(0\)\
\-\ unremarkable\\:\\ 0\\.04103518866502204\ \(0\)\
\-\ past\\:\\ 0\\.03984310601150464\ \(0\)\
\-\ area\\:\\ 0\\.03965276147675068\ \(0\)\
\-\ approximately\\:\\ 0\\.03905647520302515\ \(0\)\
\-\ medical\\:\\ 0\\.038901441046048764\ \(0\)\
\-\ show\\:\\ 0\\.038857553901949164\ \(0\)\
\-\ clinical\\:\\ 0\\.038792057919719514\ \(0\)\
\-\ treated\\:\\ 0\\.038117233361266614\ \(0\)\
\-\ year\\:\\ 0\\.037727470099272235\ \(0\)\
\-\ abdomen\\:\\ 0\\.03734833652733228\ \(0\)\
\-\ loss\\:\\ 0\\.03729141123852503\ \(0\)\
\-\ on\\:\\ 0\\.03697297692196044\ \(0\)\
\-\ carcinoma\\:\\ 0\\.03661309065771815\ \(0\)\
\-\ all\\:\\ 0\\.03643688978932131\ \(0\)\
\-\ include\\:\\ 0\\.0364194277972265\ \(0\)\
\-\ he\\:\\ 0\\.03624635321004303\ \(0\)\
\-\ shows\\:\\ 0\\.03592500934812278\ \(0\)\
\-\ presented\\:\\ 0\\.035694239340525326\ \(0\)\
\-\ distal\\:\\ 0\\.035564565354258476\ \(0\)\
\-\ significant\\:\\ 0\\.03534133964466227\ \(0\)\
\-\ enhancement\\:\\ 0\\.03523144440112898\ \(0\)\
\-\ due\\:\\ 0\\.035184688807440224\ \(0\)\
\-\ cm\\:\\ 0\\.0351536312118825\ \(0\)\
\-\ who\\:\\ 0\\.034624188081381554\ \(0\)\
\-\ these\\:\\ 0\\.034565310612542983\ \(0\)\
\-\ is\\:\\ 0\\.03352558101776359\ \(0\)\
\-\ symptoms\\:\\ 0\\.033490676912088804\ \(0\)\
\-\ physical\\:\\ 0\\.033189499105006036\ \(0\)\
\-\ follow\\:\\ 0\\.03299753706656016\ \(0\)\
\-\ imaging\\:\\ 0\\.03216795747489313\ \(0\)\
\-\ exam\\:\\ 0\\.030813174298199488\ \(0\)\
\-\ case\\:\\ 0\\.030751268020101943\ \(0\)\
\-\ up\\:\\ 0\\.030278309690071618\ \(0\)\
\-\ but\\:\\ 0\\.030268469806966486\ \(0\)\
\-\ after\\:\\ 0\\.02969400301517987\ \(0\)\
\-\ presents\\:\\ 0\\.029445197898724813\ \(0\)\
\-\ images\\:\\ 0\\.028313727427712612\ \(0\)\
\-\ male\\:\\ 0\\.027253072896812988\ \(0\)\
\-\ disease\\:\\ 0\\.025693808248991437\ \(0\)\
\-\ as\\:\\ 0\\.024590253054076097\ \(0\)\
\-\ there\\:\\ 0\\.02435529249818538\ \(0\)\
\-\ not\\:\\ 0\\.024164275244399964\ \(0\)\
\-\ are\\:\\ 0\\.023226433559931644\ \(0\)\
\-\ pain\\:\\ 0\\.021903211707903353\ \(0\)\
\-\ old\\:\\ 0\\.018115715491586467\ \(0\)\
